Liminatus Pharma Class A (LIMN)
Develops oncology antibodies and autologous CAR-T candidates through a license- and partner-dependent model.
Something off on this page? Send us feedback.
Develops an in-licensed anti-CD47 antibody and acquired CAR-T and antibody programs for cancer, with future revenue dependent on clinical development and commercialization through partnerships or direct sales. Its virtual model depends on outside research, clinical, licensing, and manufacturing counterparties.
Develops oncology candidates centered on IBA101, an in-licensed anti-CD47 antibody for advanced solid cancers. An acquisition added IBC101, an autologous CD19×CD22 CAR-T program for B-cell malignancies, plus preclinical solid-tumor CAR-T candidates INC101 and INC102 and a CS1 antibody platform.
Operates from Fullerton, California, with a development footprint tied to South Korean scientific leaders, regulators, and clinical sites. The intended model is to advance therapies through clinical development and commercialize approved products directly or through alliances, licensing, and collaboration arrangements, while using third-party GMP manufacturers rather than internal production.
The latest annual filing described a virtual organization with one full-time employee and substantial reliance on advisers, external researchers, clinical sites, licensed IP, and outsourced manufacturing. The portfolio remains pre-revenue, and IBA101's license can be terminated for uncured material breach or insolvency.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $3.0M · Total debt $1.4M · Total assets $3.4M · Shareholders' equity $300.6K
- Revenue
- $0
- Operating income
- −$1.4M
- Net income
- −$1.4M
No dividends on record.
| Institutions15 holders · as of Mar 31, 2026 | 2.20% | 29.5K shares | |
| Insiders1 holder · as of Apr 30, 2025 | 9.19% | 123.4K shares | |
| Strategic holders4 holders · as of Jul 14, 2026 | 32.23% | 432.9K shares | |
| Otherremainder | 56.38% | 757.4K shares |
1.34M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Iris Acquisition Holdings LLCStrategic10 percent owner | 10.27% | 138,000 | Form 4filed Aug 15, 2025 ↗ |
Chris KimInsiderdirector, 10 percent owner, officer: Chief Executive Officer | 9.19% | 123,388 | Form 4filed Apr 30, 2025 ↗ |
Ewon Comfortech Co., Ltd.Strategic10 percent owner | 8.19% | 110,000 | Form 4filed Jul 6, 2026 ↗ |
Valetudo Therapeutics LLCStrategic10 percent owner | 7.81% | 104,887 | Form 4filed Jul 14, 2026 ↗ |
KH Feelux Co., LtdStrategic10 percent owner | 5.96% | 80,000 | Form 4filed Jun 27, 2025 ↗ |
| See all 23 → | |||
Form 4 — an insider's transaction report
Insider tradesForm 4
No open-market trades in the last 12 months.
- Gilead Sciences
Commercial CAR-T alternative in relapsed/refractory DLBCL.
- Bristol-Myers Squibb
Commercial CD19 CAR-T alternative across relapsed B-cell lymphoma.
- Novartis (ADR)
Established autologous CAR-T alternative for relapsed DLBCL.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Liminatus Pharma Class A | $3.88 | +1.04% | $5.2M | — | — | — | — |
| Gilead Sciences | $149.20 | −0.27% | $185.75B | — | 16.5 | 6.1 | +10.2% |
| Bristol-Myers Squibb | $67.64 | −0.02% | $138.21B | 14.9 | 10.6 | 2.8 | +5.7% |
| Novartis (ADR) | $161.87 | −0.35% | $308.79B | 24.5 | 17.3 | 5.6 | +0.9% |
| Median | 19.7 | 16.5 | 5.6 | +5.7% |